# Progress Note 06 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Gilda Radner (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML026-SYN
- Date: 2026-09-15
- Fictional facility: St. Posthumous Health Center
- Fictional author: Delia Marchand, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

End of chemotherapy: CT and CA-125 results, and the maintenance decision. **S**

## History of present illness

Ms. Radner returns three weeks after her sixth and last cycle, all given on schedule. The CT a week ago shows no evidence of disease. Her energy is coming back, she walks most days, and her appetite is good. The tingling in her toes and fingertips is a little less than at cycle 4 and does not affect her hands or balance. Hot flashes continue at night. She saw Dr. Varghese with the CT result, and together they reviewed maintenance with olaparib, which she wants to start. She has no fever, cough, breathlessness, or bleeding. She has had no thoughts of self-harm. **S**

| Element | Detail |
|---|---|
| Treatment | Six cycles of carboplatin and paclitaxel completed on schedule |
| Response | CT: no evidence of disease; CA-125 9 U/mL |
| Neuropathy | Mild tingling, slowly improving |
| Menopause | Hot flashes at night |
| Decision | Starts olaparib maintenance today |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy improving; no fever or weight loss |
| Respiratory | Negative | No cough or breathlessness |
| Gastrointestinal | Negative | No nausea, bloating, or early fullness |
| Neurological | Positive | Mild tingling in the toes and fingertips, improving |
| Endocrine | Positive | Hot flashes at night |
| Psychiatric | Negative | Mood good; PHQ-9 3; no thoughts of self-harm |

6 systems reviewed. **S**

## Current medications

- Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nausea **S**
- Olaparib 150 mg oral tablet, two tablets (300 mg) by mouth twice daily with food, as maintenance for up to two years **S**

## Allergies

- No known allergy **S**

## Objective

BP 114/72 mmHg; pulse 76 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 56.8 kg; BMI 22.2 kg/m². All vital signs are synthetic.

Hemoglobin: 11.2 g/dL (low); White cell count: 4.8 10*3/uL; Absolute neutrophil count: 2.6 10*3/uL; Platelets: 214 10*3/uL; Creatinine: 0.69 mg/dL; eGFR: 113 mL/min/1.73 m²; ALT: 19 U/L; Total bilirubin: 0.4 mg/dL; CA-125: 9 U/mL; PHQ-9: 3. All results are synthetic.

## Change since baseline

- Hemoglobin: 12.4 g/dL at baseline, 11.2 g/dL (low) at this visit **S**
- White cell count: 7.8 10*3/uL at baseline, 4.8 10*3/uL at this visit **S**
- Platelets: 412 10*3/uL (high) at baseline, 214 10*3/uL at this visit **S**
- Creatinine: 0.72 mg/dL at baseline, 0.69 mg/dL at this visit **S**
- eGFR: 109 mL/min/1.73 m² at baseline, 113 mL/min/1.73 m² at this visit **S**
- ALT: 18 U/L at baseline, 19 U/L at this visit **S**
- Total bilirubin: 0.5 mg/dL at baseline, 0.4 mg/dL at this visit **S**
- CA-125: 1240 U/mL (high) at baseline, 9 U/mL at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 56.8 kg; blood pressure 114/72, pulse 76 |
| Abdomen | Soft, non-tender; no fluid or mass |
| Lymph nodes | No supraclavicular or inguinal nodes |
| Neurological | Pinprick slightly reduced over the toes only; vibration and reflexes normal; steady gait |
| Psychiatric | Bright and funny; organized |

All examination findings are synthetic. **S**

## Assessment and plan

1. **High-grade serous ovarian cancer, stage IIIC, complete response after surgery and chemotherapy** (C56.3). Complete clinical response: no evidence of disease on CT and CA-125 9 U/mL. With a tumor BRCA1 pathogenic variant, olaparib maintenance for two years lowers the risk of recurrence substantially, as Dr. Varghese advised. Baseline blood count before olaparib: hemoglobin 11.2 g/dL, neutrophils 2.6, platelets 214; creatinine 0.69 mg/dL. No interacting medicines; no grapefruit. She can no longer become pregnant. **S**
   - Olaparib 300 mg twice daily with food, starting today, for two years.
   - Blood count monthly for the first year, the first in four weeks at the preventive visit.
   - Report breathlessness, new cough, fever, bruising, or marked tiredness.
   - Surveillance with gynecologic oncology every three months for two years, with examination and CA-125; imaging only for symptoms or a rising CA-125.
2. **Chemotherapy-induced peripheral neuropathy, grade 1** (G62.0). Improving after the last paclitaxel. **S**
   - Review at each visit.
3. **Symptomatic surgical menopause** (E89.41). Hot flashes at night. Menopausal hormone therapy was discussed: it may be considered after high-grade serous ovarian cancer and would also protect her bones; she would rather wait and see how she feels on olaparib. **S**
   - Revisit at the next visit.
   - Bone density scan to be ordered at the preventive visit.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | Response imaging (CT of the chest, abdomen and pelvis) | At the end of primary treatment | Up to date | A week ago: no evidence of disease |
| Laboratory | CA-125 | At diagnosis; before each cycle when raised at diagnosis; at the end of treatment; then at each surveillance visit | Completed today | 9 U/mL, from 21 at cycle 4 |
| Laboratory | Blood count before a PARP inhibitor | Baseline, then monthly for the first year | Completed today | Hemoglobin 11.2 g/dL, white cells 4.8, neutrophils 2.6, platelets 214; recovered from chemotherapy |
| Laboratory | Kidney and liver function before a PARP inhibitor | Baseline, then as indicated | Completed today | Creatinine 0.69 mg/dL, eGFR 113; ALT 19 U/L, bilirubin 0.4 mg/dL; no dose change needed |
| Medication safety | Olaparib safety: interactions, nausea and fatigue, anemia, pneumonitis, and the rare risk of a bone marrow disorder | At the start and each visit | Completed today | No strong CYP3A inhibitors or inducers; no grapefruit; counseled on symptoms to report; ondansetron for nausea |
| Laboratory | Monthly blood count on olaparib | Monthly for the first year | Ordered | First check in four weeks, at the preventive visit |
| Examination | Peripheral neuropathy: symptoms and examination | At each visit after taxane treatment | Completed today | Grade 1, improving |
| Survey | Distress and depression screen (PHQ-9) | At diagnosis, at each treatment phase, and when symptoms change | Completed today | PHQ-9 3 |
| Self-management | Menopausal symptoms after oophorectomy | Each visit after surgery | Completed today | Hot flashes at night; hormone therapy discussed and deferred by her choice |
| Imaging | Bone density (baseline after surgical menopause) | Once after treatment, then by result | Due | To be ordered at the preventive visit next month |
| Self-management | Survivorship care plan | At the end of treatment | Completed today | Written plan given: visits every three months for two years with examination and CA-125, symptoms to report (bloating, early fullness, pelvic or abdominal pain, change in bowel habit), and support resources |

## Goal progress

- Tissue diagnosis and gynecologic oncology plan within two weeks of presentation. Outcome by 2026-04-14: Ultrasound, CT and biopsy within four days; diagnosis and consultation on the eighth day. **S**
- Cytoreductive surgery with no visible residual disease within three weeks of diagnosis. Outcome by 2026-05-12: Complete gross resection one week after the diagnosis. **S**
- Six cycles of carboplatin and paclitaxel every three weeks without a delay of more than one week. Outcome by 2026-09-15: Six cycles completed on schedule; CT shows no evidence of disease and CA-125 is 9. **S**
- Germline and tumor genetic results available before the maintenance decision. Outcome by 2026-09-15: Germline panel negative; tumor BRCA1 pathogenic variant; olaparib started. **S**
- PHQ-9 below 10 throughout treatment, with a peer-support connection. Outcome by 2026-09-15: PHQ-9 between 3 and 7; attends a cancer support community group. **S**

## Medication changes

- Started: Olaparib 150 mg oral tablet, two tablets (300 mg) by mouth twice daily with food, as maintenance for up to two years **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 4.2026 (2026), National Comprehensive Cancer Network
- Tew WP, et al. PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline. J Clin Oncol 2020;38(30):3468-3493 (2020), American Society of Clinical Oncology
- Salani R, et al. An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations. Gynecol Oncol 2017;146(1):3-10 (2017), Society of Gynecologic Oncology
- Loprinzi CL, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol 2020;38(28):3325-3348 (2020), American Society of Clinical Oncology
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force

## Follow-up

- Preventive visit in four weeks with the first monthly blood count. Gynecologic oncology surveillance every three months. Call for breathlessness, new cough, fever, bruising, or the return of bloating or early fullness. **S**
- Next scheduled visit 2026-10-13: periodic adult preventive visit after ovarian cancer treatment. **S**
